GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) has been given an average rating of “Moderate Buy” by the fifteen ratings firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $8.38.
A number of analysts recently commented on the stock. Citigroup lowered their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Morgan Stanley dropped their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Mizuho initiated coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective for the company. KeyCorp decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Barclays dropped their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th.
View Our Latest Analysis on GoodRx
Institutional Trading of GoodRx
GoodRx Trading Up 3.4 %
Shares of NASDAQ:GDRX opened at $4.57 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a market capitalization of $1.74 billion, a P/E ratio of -152.33, a P/E/G ratio of 2.30 and a beta of 1.27. The business’s 50-day moving average is $4.59 and its 200 day moving average is $6.45. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26.
About GoodRx
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Further Reading
- Five stocks we like better than GoodRx
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What is the Euro STOXX 50 Index?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.